-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
E-Mail
ShareEntry Inhibitors in Development
- CCR5 Antagonist Vicriviroc Fails to Surpass Potent Background Regimen (February 18, 2010)
From aidsmap.com - New CCR5 Antagonist TBR-652 Shows Good Antiviral Activity in Early Study (February 18, 2010)
From aidsmap.com - Why Vicriviroc Failed in Its Phase 3 Trials -- and What It May Mean for Future Studies in HIV Treatment-Experienced People (Feb. 17, 2010; 11:36 a.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC - Incyte Halts Development of Promising New CCR5 Drug (April 10, 2008)
From Project Inform - CCR5 Inhibitors in Development: New Data on SCH532706 and Vicriviroc (February 3, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Schering-Plough Launches Phase III Trials of Experimental Antiretroviral Vicriviroc (September 19, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - CCR5 Entry Inhibitors: Vicriviroc (July 25, 2007)
Edwin DeJesus takes a look at recent data on vicriviroc, a CCR5 entry inhibitor currently being studied in treatment-experienced patients.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - CCR5 Antagonists: INCB009471 and Vicriviroc (July 24, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Orally Bioavailable Fusion Inhibitors in Development (July 23, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy (December 19, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - No Difference in HAART Response in Patients With X4-Using HIV (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Aplaviroc's Potency Against HIV Is Linked to Its Slow Dissociation From the CCR5 Receptor (August 17, 2006)
In XVI International AIDS Conference - Co-Receptor Conundrum: The Challenges of Turning Theory Into Reality (April 2006)
At the moment, there are many more questions than answers about an investigational class of drugs known as co-receptor inhibitors.
To read PDF, click here.
In TAGline, from Treatment Action Group - Entry Inhibitors in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body